Search
Selected Filters
Filter Results
Displaying 91–100 of 268 research results
-
Apr 9, 2021
Foundation Invests $5.5 Million in Seven New Translational Research Projects
Projects target a variety of conditions including: age-related macular degeneration, Stargardt disease, retinitis pigmentosa, and Usher syndrome type 3A
-
Mar 30, 2021
Bionic Sight’s Optogenetic Therapy Enables Blind Patients to Detect Light and Motion in Early Trial
The approach holds potential for restoring vision to people with little or no vision
-
Mar 24, 2021
ProQR’s RNA Therapy for USH2A Performs Well in Phase 1/2 Clinical Trial
The company is planning two Phase 2/3 clinical trials for the treatment
-
Mar 16, 2021
Foundation’s No-Cost Program Increased Genetic Testing Rates for IRD Patients
More than 8,000 people have applied for genetic testing through the Foundation’s program
-
Feb 17, 2021
A Eureka Moment for Paul Yang Boosts Advancement of Vision-Saving RP Drug
His latest Foundation grant is helping move the drug toward a clinical trial
-
Feb 11, 2021
Are You on the Clinical Trial Radar Screen?
Therapy developers use the My Retina Tracker Registry to recruit for human studies of emerging therapies
-
Feb 2, 2021
Very-Long-Chain Polyunsaturated Fatty Acids Improve Vision in Mice with a Form of Stargardt Disease
Researchers believe the VLC-PUFAs may benefit people with autosomal dominant Stargardt disease, AMD, and possibly other retinal degenerations
-
Jan 28, 2021
The company plans to enroll additional patients as young as four years old
-
Jan 26, 2021
Genentech’s Faricimab Performs Well in Phase 3 Clinical Trials for Wet AMD
Company will seek marketing approval for the emerging therapy
-
Jan 13, 2021
ProQR Completes Enrollment in Phase 2/3 Clinical Trial of RNA Therapy for LCA10
Company also announced progress in enrollment for Phase 1 / 2 clinical trials for emerging USH2A and RHO RNA therapies.